Bacterial Endotoxin Testing Service – Accredited LAL Assay and Pharmacopoeial Compliance for Global Markets
Our internationally accredited laboratory provides a specialist bacterial endotoxin testing service that enables pharmaceutical manufacturers, medical‑device producers, biotechnology companies, parenteral‑nutrition suppliers and regulatory‑compliance teams worldwide to quantify the pyrogenic endotoxin burden in their raw materials, in‑process samples, water systems and finished products. Every assay is conducted under the rigorous framework of ISO/IEC 17025, and each report bearing the ILAC mark is unconditionally accepted by regulatory authorities, notified bodies and supply‑chain partners in all major economies. The bacterial endotoxin testing service employs the Limulus amebocyte lysate methodology in its gel‑clot, kinetic‑turbidimetric and kinetic‑chromogenic configurations, all harmonised with the United States Pharmacopeia Chapter ⟨85⟩, the European Pharmacopoeia Chapter 2.6.14 and the Japanese Pharmacopoeia, and it directly supports the batch release, the water‑system validation and the demonstration of compliance with the FDA, EMA and PIC/S GMP requirements on every continent.
Product Samples We Regularly Subject to Bacterial Endotoxin Testing
The aseptic‑sampling, dilution and inhibition‑enhancement control procedures in our laboratory accommodate an extraordinarily diverse range of pharmaceutical and medical‑device matrices. The following categories represent the most frequently tested items:
- Water for injection, purified water and clean‑steam condensate – the samples drawn from the pharmaceutical water‑generation and distribution loops, tested as part of the routine monitoring and the periodic system validation
- Active pharmaceutical ingredients and excipients – the small‑molecule drugs, the peptides, the amino‑acids, the sugars, the starches and the inorganic salts that are used in the formulation of the parenteral products
- Parenteral finished dosage forms – the solutions, the emulsions, the suspensions and the lyophilised powders for injection, including the small‑volume and the large‑volume parenterals
- Ophthalmic, intra‑articular and intrathecal preparations – the high‑risk, low‑endotoxin‑limit products that require the most sensitive kinetic methods
- Medical devices and combination products – the catheters, the syringes, the infusion sets, the dialysis cartridges and the drug‑eluting stents, extracted with the pyrogen‑free water according to the ISO 10993‑12 and the ANSI/AAMI ST72 recommendations
- Biopharmaceuticals and cell‑therapy products – the monoclonal antibodies, the recombinant proteins, the vaccines, the viral‑vector and the cell‑based preparations that are inherently sensitive to the endotoxin interference and may require the specific pretreatment or the high‑dilution testing
- In‑process and the cleaning‑validation samples – the swabs, the rinsates and the in‑process‑hold‑time samples from the manufacturing‑equipment surfaces and the cleanroom environments
Gel‑Clot, Kinetic‑Turbidimetric and Kinetic‑Chromogenic Methods – Bacterial Endotoxin Testing According to USP ⟨85⟩, Ph. Eur. 2.6.14 and JP 4.01
- Qualitative and semi‑quantitative gel‑clot limit test according to the harmonised pharmacopoeial monographs: the test sample, diluted to the maximum valid dilution, is mixed with a lysate of a certified sensitivity and incubated at 37 °C ± 1 °C for 60 minutes. After the incubation, each tube is gently inverted and examined for the formation of a firm gel that remains intact. The presence or the absence of the gelation is recorded, and the sample is reported as either “pass” or “fail” relative to the specified endotoxin limit. This bacterial endotoxin testing method is the simplest, most robust configuration and is used for the routine in‑process control and the batch‑release of the majority of the parenteral drugs.
- Quantitative kinetic‑turbidimetric and the kinetic‑chromogenic assays for the precise endotoxin determination: the test sample is incubated with the lysate in a microplate reader that continuously monitors the turbidity or the colour development at the controlled temperature. The time required for each reaction to reach a defined threshold optical density – the onset time – is inversely proportional to the endotoxin concentration in the sample, and the concentration in the endotoxin units per millilitre is calculated from a concurrently run standard curve prepared from the certified reference endotoxin. The method achieves a quantification range of typically 0.005 EU/mL to 50 EU/mL and is mandatory for the high‑sensitivity products such as the intrathecal injections and the ophthalmic solutions. The bacterial endotoxin testing report provides the individual and the mean endotoxin concentration for each replicate, together with the coefficient of variation and the spike‑recovery data.
- Inhibition and the enhancement screening (the product‑validation test): for every new product formulation or the new dilution scheme, the test sample is spiked with a known concentration of the endotoxin standard at several dilutions, and the recovery of the spiked endotoxin is measured. The dilution that yields a recovery between 50 % and 200 % of the spiked value is identified as the valid, interference‑free dilution for the routine testing. This bacterial endotoxin testing validation is a regulatory requirement and must be performed before any product batch can be released using the LAL method.
- Determination of the maximum valid dilution and the minimum valid concentration: the endotoxin limit for the product is calculated from the patient‑dose‑based formula prescribed by the pharmacopoeia, and the maximum dilution that still allows the detection of the limit concentration is determined, ensuring that the test is performed within the validated sensitivity range of the lysate and that no false‑negative result is obtained due to the excessive dilution.
- Low‑endotoxin‑recovery studies and the investigation of the product‑induced masking: for the products that exhibit a time‑dependent or a matrix‑dependent inhibition of the endotoxin detection – such as the chelating‑agent‑containing formulations, the surfactant‑containing biopharmaceuticals and the citrate‑anticoagulated samples – a hold‑time study and a serial‑dilution recovery experiment are conducted to identify the conditions under which the endotoxin is fully recoverable, supporting the regulatory submission and the defence of the LAL method against the proposed replacement by the recombinant factor‑C assay.
- Recombinant factor‑C and the alternative‑method validation: for the customers who are transitioning to the animal‑free, recombinant‑factor‑C or the monocyte‑activation test, we offer the side‑by‑side comparability testing against the LAL method, and the correlation, the sensitivity and the specificity of the alternative method are documented, providing the data package that the FDA and the EMA require for the acceptance of the alternative endotoxin test.
Report Acceptance and Global Regulatory Compliance
All bacterial endotoxin testing described above is executed under the fully accredited scope of our ISO/IEC 17025 quality management system. Each test report that carries the ILAC mark is therefore automatically recognised by regulatory authorities, notified bodies, customs offices and supply‑chain partners in all major economies. For pharmaceutical manufacturers, medical‑device producers, biotechnology companies and parenteral‑drug formulators anywhere in the world, the report constitutes legally robust, internationally accepted evidence that the endotoxin concentration, the gel‑clot limit‑test result and the inhibition‑enhancement validation have been determined in accordance with the applicable USP, Ph. Eur., JP and customer‑specified methods. The documentation can be directly used to support the product batch release, the marketing‑authorisation application, the water‑system qualification, the issue of inspection certificates according to EN 10204 or equivalent national standards, and the resolution of commercial and technical disputes concerning the pyrogenicity and the parenteral safety of any pharmaceutical or medical‑device product.
